VisionGate

Executive Summary

VisionGate is a privately held biotechnology company based in Phoenix, Arizona, focused on revolutionizing lung cancer detection through its proprietary Cell-CT platform. The company's non-invasive test leverages 3D cellular imaging and artificial intelligence to identify malignant cells at the earliest stages, when the chance for cure is highest. Founded in 2007, VisionGate aims to address the critical unmet need for early lung cancer screening, potentially reducing mortality by enabling timely intervention. The Cell-CT technology analyzes intact cells in three dimensions, providing superior sensitivity and specificity compared to traditional 2D cytology. By integrating AI-based image analysis, VisionGate's platform minimizes human error and enhances diagnostic accuracy. With lung cancer remaining the leading cause of cancer deaths worldwide, VisionGate's innovative approach could significantly impact public health. The company is currently in a growth phase, seeking to commercialize its technology and secure regulatory approvals to bring its test to market.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval for Cell-CT Lung Cancer Screening Test40% success
• Q2 2026Publication of Large-Scale Clinical Validation Study Results60% success
• Q3 2026Strategic Partnership or Licensing Agreement with Major Diagnostics Company35% success